智通财经APP讯，国锐生活(00108)发布公告，内容有关本公司与卖方就本集团可能收购潜在标的(主要 从事数字医疗服务)的100%股权订立不具法律约束力的意向书。董事局欣然宣布，于2025年12月5日， 本公司并表附属实体中国经营实体(作为买方)与卖方订立该等协议，中国经营实体有条件同意购买而卖 方有条件同意出售销售股份(目标公司北京春雨天下软件已发行股本总额约78.3%)，代价约为人民币2.69 亿元(相当于约2.948亿港元)，将透过按发行价每股代价股份1.6港元发行及配发1.47亿股代价股份偿付， 惟须符合先决条件。 为维持建议收购事项完成后目标集团现有业务规模并进一步扩展，本公司拟保留目标集团现有管理团 队，并聘请行业专家及专业人士协助目标集团数字医疗服务业务的运营及管理。董事局相信，保留目标 集团现有运营知识，同时引入额外专业知识并结合本集团资源，将有助实现顺利整合，并支持目标集团 的长期增长。 为配合本集团战略及最大化协同价值，本公司正与目标公司两名剩余股东("剩余股东")进行磋商，该等 股东合共持有目标公司约12.76%股权("剩余股份")。本公司与剩余股东已表示有意就剩余股份订立单独 买卖协议 ...

为配合集团战略及最大化协同价值，公司正与目标公司两名剩余股东("剩余股东")进行磋商，该等股东 合共持有目标公司约12.76%股权。公司与剩余股东已表示有意就剩余股份订立单独买卖协议，其条款 及条件将与股份买卖协议及╱或现金买卖协议(如适用)基本一致。公司将根据上市规则适时或按规定作 出进一步公布，以告知股东。 从财务角度看，数字医疗服务通常具有经常性服务费及平台收入特性，长远而言相较更具周期性的开发 收入可提升集团收入可见度及整体毛利水平。 目标集团通过具备正规牌照的医疗机构经营增值电信服务(包括互联网信息服务)及互联网医院╱在线诊 断与治疗服务。此商业模式属规模化，受益于相关监管牌照(包括ICP许可证及《医疗机构执业许可 证》)，预计可提供反周期收入来源，与集团现有房地产相关业务形成互补。集团通过进入高增长行 业，寻求降低传统房地产周期带来的集中风险，提升整体业务韧性。 目标集团在中国数字医疗服务领域拥有稳固客户基础及丰富经验，而公司于中国已建立成熟的客户群、 资源及网络(包括物业管理平台及社区覆盖)。公司拟利用现有资源、市场地位及关系，协助目标集团扩 展服务范围、吸纳新用户及企业客户，从而进一步扩大目标 ...

Group 1 - The core point of the article highlights that on November 7, the shareholder of Guorui Life (00108) transferred shares from UBS Securities Hong Kong Limited to Ding Shi Securities, with a transfer market value of HKD 857 million, accounting for 13.37% of the total shares [1] - Guorui Life announced a non-binding letter of intent with a potential seller regarding the possible acquisition of 100% equity of a target company, which is a limited liability company registered in the People's Republic of China, primarily engaged in digital healthcare services [1]

Core Viewpoint - Health 160 (02656) has seen a significant stock price increase, rising over 256% from its IPO price of 11.89 HKD to a peak of 42.34 HKD, indicating strong market interest and confidence in the company's business model and growth potential [1] Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of digital healthcare integrated services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] Digital Healthcare Platform - Health 160 operates an online healthcare service platform that provides digital healthcare solutions, empowering various participants in the healthcare industry [1] - As of March 31, 2025, the platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals (of which 3,430 are tertiary hospitals) and over 30,200 grassroots healthcare institutions [1] - Among the partnered healthcare institutions, over 6,800 private entities primarily offer consumer medical services such as dental, ophthalmology, and health check-up services through the platform [1]

Core Viewpoint - Health 160 International Limited (Health 160) has successfully listed on the Hong Kong Stock Exchange, with a closing price of 28.22 HKD, reflecting a significant increase of 137.34% from its opening price of 29.98 HKD. The company operates as a wholesaler of pharmaceutical health products and a provider of digital healthcare solutions in China [1]. Group 1: IPO Details - Health 160 issued a total of 33,645,500 shares in its global offering, with 3,364,750 shares allocated for the Hong Kong public offering and 30,280,750 shares for international offering [2]. - The final offer price for the shares was set at 11.89 HKD, resulting in total proceeds of 400 million HKD. After deducting estimated listing expenses of 83.9 million HKD, the net proceeds amounted to 316.1 million HKD [3]. Group 2: Use of Proceeds - The net proceeds from the global offering are intended to be used for expanding healthcare resource coverage, enhancing research and development capabilities, diversifying product and service offerings, exploring strategic partnerships and acquisitions, and for general working capital purposes [3]. Group 3: Financial Performance - Health 160 reported revenues of 525.6 million RMB, 628.6 million RMB, and 620.7 million RMB for the years 2022, 2023, and 2024 respectively, with quarterly revenues of 94.2 million RMB and 100.5 million RMB for the first quarters of 2024 and 2025 [5]. - Despite revenue growth, the company recorded operating losses of 79.2 million RMB, 99.5 million RMB, and 104.6 million RMB for the years 2022, 2023, and 2024, respectively, indicating ongoing challenges in achieving profitability [6]. - The adjusted net losses for the same periods were 118.9 million RMB, 111.2 million RMB, and 108.2 million RMB, with quarterly adjusted net losses of 40.6 million RMB and 17.1 million RMB for the first quarters of 2024 and 2025 [7].

Group 1 - The core viewpoint of the article highlights the successful listing of Health 160 (02656) with a share price of HKD 11.89, raising approximately HKD 316 million from the issuance of 33.6455 million shares [1] - As of the report, the stock price surged by 152.14%, reaching HKD 29.98, with a trading volume of HKD 101 million [1] - Health 160 is described as an experienced wholesaler of pharmaceutical health products and a leading provider of digital healthcare services in China [1] Group 2 - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various stakeholders in the healthcare industry [1] - As of March 31, 2025, the platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [1] Group 3 - Among the partnered healthcare institutions, over 6,800 private entities provide consumer medical services such as dental, ophthalmology, and health check-up services through the platform [1]

Core Viewpoint - Health 160 (02656) was listed on the Hong Kong Stock Exchange on September 17, 2023, opening with a significant increase of 150.97%, resulting in a total market capitalization of HK$100.4 billion [1]. Company Overview - Health 160 is a Chinese wholesale distributor of medical health products and a provider of comprehensive digital healthcare solutions, offering a variety of medical health products and digital healthcare services to clients [2]. - As of March 31, 2025, Health 160 has connected over 44,600 healthcare institutions, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [3]. - The company has established partnerships with over 902,300 healthcare professionals, including approximately 46,200 registered doctors, and has a registered user base of 55.2 million individuals [3]. Financial Performance - Health 160's revenue for the years 2022, 2023, and 2024 was RMB 525.646 million, RMB 628.606 million, and RMB 620.682 million, respectively, with corresponding losses of RMB 120.065 million, RMB 106.199 million, and RMB 108.246 million [4]. - In the first quarter of 2025, the company reported revenue of RMB 100.475 million, a year-on-year increase of 6.7%, with a loss of RMB 17.128 million compared to a loss of RMB 40.246 million in the same period the previous year [4][3]. Shareholding Structure - Prior to the IPO, Roning Zheng controlled approximately 33.99% of the voting rights through his wholly-owned companies, LNZ Management Limited and Luo Holdings Limited [5]. - Following the share split and global offering, Roning Zheng is expected to control about 34.08% of the company's issued share capital [5][6]. Leadership - Roning Zheng, the founder, executive director, chairman, and CEO of the group, has over 25 years of industry experience and is responsible for the overall strategy and management of the company [7].